Composition for treating radiation bowel disease and application thereof
The Wnt/β-catenin signaling pathway and inhibit the Caspase-9/-3 signaling pathway through the puerarin, baicalin, berberine and glycyrrhizic acid in the composition, affecting the NF-κB signaling pathway, and solving the existing technology The lack of treatment of radiation enteropathy significantly alleviates the intestinal pathological effects of radiation damage.
Patent Information
- Application Number
- CN202410879634.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-02
AI Technical Summary
The prior art lacks effective drugs for the treatment of radiation enteropathy, especially due to the severe side effects of Amifostine and the narrow treatment time window, resulting in limited clinical application.
Using a composition, including puerarin, baicalin, berberine and glycyrrhizic acid, promotes cell proliferation by activating the Wnt/β-catenin signaling pathway, inhibits the Caspase-9/-3 signaling pathway to reduce cell apoptosis, and affects The NF-κB signaling pathway reduces cellular inflammatory response and is used to treat radiation enteropathy.
This composition significantly reduces the degree of intestinal villi shortening, the number of crypts, reduces Chiu's score, reduces intestinal pathological damage caused by radiation, improves radiation damage to intestinal epithelial cells, and has a significant effect in treating radiation enteropathy. .
Smart Images

Figure BDA0004924113680000061 
Figure BDA0004924113680000071
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to a composition for treating radiation enteropathy and application thereof. Background Art
[0002] Radiation-induced intestinal injury (RII) is intestinal damage caused by ionizing radiation, including x-rays, gamma rays, beta rays, and neutron rays. The pathogenesis of RII involves factors such as apoptosis and senescence of intestinal epithelial cells, activation of intestinal inflammation, activation of oxidative stress, changes in intestinal flora, and intestinal tissue fibrosis. The pathological mechanism is complex and the pathological process is diverse. There is currently no ideal treatment measure.
[0003] In clinical treatment of RII, free radical oxidative damage drugs such as vitamin C and vitamin E are often used. Amifostine, as a free radical scavenger, can reduce the side effects of radiotherapy and is currently the only drug approved for clinical anti-RII. However, its severe side effects and narrow treatment time window severely limit its clinical use. Therefore, further searching for possible effective drugs for RII treatment has great clinical value. Summary of the invention
[0004] In order to solve the above technical problems, the purpose of the present invention is to provide a composition for treating radiation enteropathy and its application, so as to solve the problem of lack of effective therapeutic drugs for radiation intestinal injury.
[0005] The technical solution of the present invention to solve the above technical problems is as follows:
[0006] A composition for treating radiation enteropathy, comprising puerarin, baicalein, berberine and glycyrrhetinic acid.
[0007] The beneficial effects of the present invention are as follows: the present invention provides a composition for treating radiation enteropathy, which can effectively reduce the shortening of intestinal villi caused by radiation enteropathy, restore the number of crypts, reduce Chiu's score, and reduce intestinal pathological damage caused by radiation; the composition promotes the proliferation of HIEC-6 cells after radiation damage by activating the Wnt / β-catenin signaling pathway, reduces HIEC-6 cell apoptosis by inhibiting the Caspase-9 / -3 signaling pathway, and reduces the cellular inflammatory response caused by radiation damage by affecting the NF-κB signaling pathway, thereby playing a significant role in treating radiation enteropathy.
[0008] Furthermore, the molar ratio of puerarin, baicalein, berberine and glycyrrhetinic acid in the composition is (180-260): (100-200): (5-30): (1-10).
[0009] Furthermore, the molar ratio of puerarin, baicalein, berberine and glycyrrhetinic acid in the composition is 220:150:15:5.
[0010] Application of the composition for treating radiation enteropathy in preparing medicine for treating radiation enteropathy.
[0011] Furthermore, radiation enteropathy includes acute / chronic enteropathy caused by at least one of x-rays, gamma-rays, alpha-rays, beta-rays and neutron-rays.
[0012] Furthermore, acute / chronic intestinal diseases include acute / chronic enteritis, intestinal obstruction, intestinal bleeding and intestinal ulcer.
[0013] A medicine for treating radiation enteropathy, comprising the above composition.
[0014] Furthermore, the dosage form of the drug includes an oral preparation or an enema preparation.
[0015] The present invention has the following beneficial effects:
[0016] The present invention provides a composition for treating radiation enteropathy. The composition can promote the proliferation of intestinal cells after radiation damage, reduce the level of intestinal tissue inflammation after radiation, reduce the apoptosis of intestinal cells after radiation, etc., improve the radiation damage of intestinal epithelial cells, play an anti-radiation intestinal damage effect, and has a significant effect in treating radiation enteropathy by regulating multiple pathways such as Wnt / β-catenin, NF-κB and Caspase-9 / -3 signaling pathways. DETAILED DESCRIPTION
[0017] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific conditions are specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.
[0018] Example 1: Radiation intestinal mucosal damage evaluation experiment
[0019] The radiation intestinal mucosal injury evaluation experiment was conducted by intragastric gavage.
[0020] (1) Experimental methods
[0021] C57 BL / 6J mice were irradiated whole-body at once using the X-ray 6MV mode, with a source-skin distance of 100 cm and a dose rate of 400MU / min to construct a mouse radiation injury model to simulate radiation enteropathy.
[0022] The mice were divided into a normal group, a model group, a low-dose composition group, a medium-dose composition group and a high-dose composition group.
[0023] Among them, the dosage of the low-dose group of the composition is: puerarin 2.16 mg / kg + baicalein 0.9 mg / kg + berberine 0.18 mg / kg + glycyrrhetinic acid 0.04 mg / kg;
[0024] The dosage of the combination group is: puerarin 4.32 mg / kg + baicalein 1.8 mg / kg + berberine 0.36 mg / kg + glycyrrhetinic acid 0.08 mg / kg;
[0025] The dosage of the high-dose group of the composition is: puerarin 8.64 mg / kg + baicalein 3.6 mg / kg + berberine 0.72 mg / kg + glycyrrhetinic acid 0.16 mg / kg.
[0026] After the model was established, the mice were given drugs by oral gavage for 7 days and then sacrificed. H&E staining was performed and Chiu's score, villus length and intestinal crypt number were used to evaluate the damage of intestinal tissue.
[0027] (2) Experimental results
[0028] The experimental results are shown in Table 1. ## P<0.01 compared with the normal group; ** P<0.01, * P<0.05 compared with the model group.
[0029] Table 1 Evaluation of the effect of the composition on RII intestinal mucosal pathological damage
[0030] Grouping Chiu's Rating Villus length (μm) Number of crypts Normal group 0.50±0.55 592.59±10.94 29.33±2.73 Model Group <![CDATA[4.67±0.52 ## ]]> <![CDATA[279.66±12.51 ## ]]> <![CDATA[13.5±1.05 ## ]]> Combination low dose group 4.0±0.63* 451.07±20.79** 18.67±1.37** Dosage group in the composition 3.5±0.55** 510.64±13.04** 22.33±1.63** Combination high dose group 3.0±0.63** 558.20±6.44** 24.5±1.52**
[0031] The results showed that compared with the normal control group, the intestinal villi of the mice in the radiation model group collapsed, fell off and shortened, the intestinal villus epithelial cells degenerated, necrotic and fell off, the number of crypts decreased, and the Chiu's score increased significantly (P<0.01). Compared with the model group, the shortening of the intestinal villi in the combination group was reduced, the number of crypts increased, and the Chiu's score decreased, indicating that the intestinal tissue damage was reduced, indicating that the combination can significantly reduce the intestinal pathological damage caused by radiation.
[0032] Example 2: Experimental evaluation of irradiated cell proliferation levels
[0033] The proliferation level of irradiated cells was evaluated by in vitro cell experiments.
[0034] (1) Experimental methods
[0035] Human intestinal epithelial cells HIEC-6 were inoculated in a well plate, and a cell radiation injury model was constructed using a 4Gy X-ray dose. The cell experiments were divided into a normal group, a model group, a combination group, a HY-148055A (Wnt / β-catenin agonist, purchased from MedChemExpres) group, and a combination + HY-148055A (Wnt / β-catenin agonist) group.
[0036] Among them, the dosage of the combination in the combination group and the combination + HY-148055A group was: puerarin 6.043 μg / mL + baicalein 2.34 μg / mL + berberine 0.35 μg / mL + glycyrrhizic acid 0.031 μg / mL; after 24 hours of drug intervention in each group, the expression of Ki67 was detected by immunofluorescence method.
[0037] (2) Experimental results
[0038] The experimental results are shown in Table 2. ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group.
[0039] Table 2 Effect of the composition on the proliferation of RII intestinal epithelial cells
[0040] Grouping Relative proliferation rate (%) Normal group 45.61±3.39 Model Group <![CDATA[5.23±0.73 ## ]]> Combination group 26.76±3.88** HY-148055A Group 29.52±2.40** Combination + HY-148005A group 30.19±3.74**
[0041] Ki67 is a nuclear protein that is closely related to the activity of cell proliferation and can be used as a marker for cell proliferation. The results in the above table show that compared with the normal group, the expression of Ki67 in the model group after radiation was significantly reduced (P<0.01), and cell proliferation was significantly inhibited. Compared with the model group, the combination group can promote cell proliferation, as shown by a significant increase in the expression of lipoprotein Ki67 (P<0.01). This shows that the combination can promote the proliferation of HIEC- cells after radiation damage by activating the Wnt / β-catenin signaling pathway.
[0042] Example 3: Experimental study on the evaluation of irradiated cell apoptosis level
[0043] The apoptosis level of irradiated cells was evaluated by in vitro cell experiments.
[0044] (1) Experimental methods
[0045] Human intestinal epithelial cells HIEC-6 were inoculated in a well plate, and a cell radiation injury model was established using a 4Gy X-ray dose. The cell experiments were divided into a normal group, a model group, a combination group, a HY-12305 (Caspase-9 / -3 inhibitor, purchased from MedChemExpress) group, and a combination + HY-12305 (Caspase-9 / -3 inhibitor) group.
[0046] Among them, the dosage of the combination in the combination group and the combination + HY-12305 group was: puerarin 6.043μg / mL + baicalein 2.34μg / mL + berberine 0.35μg / mL + glycyrrhizic acid 0.031μg / mL; after 24 hours of drug intervention in each group, the TUNEL experiment was used to detect the level of cell apoptosis.
[0047] (2) Experimental results
[0048] The experimental results are shown in Table 3. ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group.
[0049] Table 3 Effects of the composition on apoptosis of RII intestinal epithelial cells
[0050] Grouping Relative proliferation rate (%) Normal group 3.33±0.68 Model Group <![CDATA[18.45±2.75 ## ]]> Combination group 7.98±0.47** HY-12305 Group 6.58±1.41** Combination + HY-12305 group 5.80±0.85**
[0051] The results showed that compared with the normal group, the apoptotic cells in the model group increased significantly after radiation (P<0.01), and the cells were severely damaged. Compared with the model group, the apoptotic cells in the combination group, HY-12305 group, and combination + HY-12305 group decreased significantly (P<0.01), indicating that the combination can reduce HIEC-6 cell apoptosis by inhibiting the Caspase-9 / -3 signaling pathway.
[0052] Example 4: Experimental evaluation of the level of inflammatory factors secreted by irradiated cells
[0053] The level of inflammatory factors secreted by irradiated cells was evaluated through in vitro cell experiments.
[0054] (1) Experimental methods
[0055] Human intestinal epithelial cells HIEC-6 were inoculated in a well plate, and a cell radiation injury model was constructed using a 4Gy X-ray dose. The cell experiments were divided into a normal group, a model group, a combination group, a HY-18738 (NF-κB inhibitor, purchased from MedChemExpress) group, and a combination + HY-18738 (NF-κB inhibitor) group.
[0056] Among them, the dosage of the combination in the combination group and the combination + HY-18738 group was: puerarin 6.043 μg / mL + baicalein 2.34 μg / mL + berberine 0.35 μg / mL + glycyrrhizic acid 0.031 μg / mL; after 24 hours of drug intervention in each group, the factor level was detected by ELISA kit.
[0057] (2) Experimental results
[0058] The experimental results are shown in Table 4. ## P<0.01 compared with the normal group; ** P<0.01, * P<0.05 compared with the model group.
[0059] Table 4 Effect of the composition on the secretion of inflammatory factors in RII intestinal epithelial cells
[0060]
[0061] The results showed that compared with the normal group, the model group could lead to increased levels of pro-inflammatory factors TNF-α, IL-1β, and IL-6, and decreased levels of anti-inflammatory factors IL-10 after radiation. Compared with the model group, both the composition and the KF-κB signaling pathway inhibitor could alleviate the cellular inflammatory response to a certain extent, and the anti-inflammatory levels were comparable, indicating that the composition could alleviate the cellular inflammatory response caused by radiation damage by affecting the KF-κB signaling pathway.
[0062] Example 5: Experimental evaluation of expression levels of key proteins in each signaling pathway
[0063] On the basis of Examples 2-4, proteins were extracted from cells of each group, and changes in the expression levels of key proteins of the Wnt / β-catenin signaling pathway, the Caspase-9 / -3 signaling pathway, and the NF-κB signaling pathway were detected by immunoblotting.
[0064] The experimental results are shown in Table 5. ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group.
[0065] Table 5 Effects of the composition on RII intestinal epithelial cell-related signaling pathway proteins
[0066]
[0067] The activation of the Wnt / β-catenin signal transduction pathway is due to the increased transfer of β-catenin to the nucleus. In the nucleus, β-catenin binds to the transcription factor family TCF / LEFs, which can promote the expression of proteins such as CyclinD1 (CCND1) and MYC, and promote cell proliferation. Western blot test results showed that the composition significantly increased the expression of β-catenin in the nucleus, indicating that the composition activated the Wnt / β-catenin pathway by promoting β-catenin nuclear entry. There was no significant difference in the expression level of nuclear β-catenin in the cells of the composition + HY-148055A group and the HY-148055A group. The above results show that the composition promotes the proliferation of intestinal epithelial cells by activating the Wnt / β-catenin signaling pathway.
[0068] Compared with the normal group cells, the combination group and the combination + HY-12305 group significantly inhibited the expression levels of Caspase-3, Caspase-9, Cleaved-Caspase-3 and Cleaved-Caspase-9 proteins. The above results show that the combination plays an anti-apoptosis role in radiation-damaged cells by inhibiting the activation of the Caspase-9 / -3 signaling pathway.
[0069] Compared with the model group, the combination group, HY-18738 group and combination + HY-18738 group all significantly inhibited the protein expression level of phosphorylated P65, while there was no significant difference in the protein expression level of phosphorylated P65 between the combination + HY-18738 group and the HY-18738 group, and there was no significant effect on the expression of P65. The above results show that the combination can inhibit the phosphorylation level of P65 protein and then inhibit the activation of NF-κB signaling pathway, thereby playing an anti-inflammatory role in radiation-induced intestinal injury.
[0070] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A composition for treating radiation enteropathy, It is characterized in that The composition includes puerarin, baicalein, berberine and glycyrrhetinic acid.
2. The composition for treating radiation enteropathy according to claim 1, It is characterized in that The molar ratio of puerarin, baicalein, berberine and glycyrrhetinic acid in the composition is (180-260): (100-200): (5-30): (1-10).
3. The composition for treating radiation enteropathy according to claim 1, It is characterized in that The molar ratio of puerarin, baicalein, berberine and glycyrrhetinic acid in the composition is 220:150:15:
5.
4. Use of the composition for treating radiation enteropathy according to any one of claims 1 to 3 in the preparation of a drug for treating radiation enteropathy.
5. The use according to claim 4, It is characterized in that The radiation enteropathy includes acute / chronic enteropathy caused by at least one of X-rays, gamma-rays, alpha-rays, beta-rays and neutron-rays.
6. The use according to claim 5, It is characterized in that The acute / chronic intestinal diseases include acute / chronic enteritis, intestinal obstruction, intestinal bleeding and intestinal ulcer.
7. A drug for treating radiation enteropathy, It is characterized in that The invention comprises the composition according to any one of claims 1 to 3.
8. The drug for treating radiation enteropathy according to claim 7, It is characterized in that The dosage form of the drug includes oral preparations or enema preparations.
Citation Information
Patent Citations
A pueraria root scutellaria and coptis medicinal composition
CN101156906A
Glycyrrhizic acid, biogastrone acid or its salt, derivative temperature sensing gel rubber, preparation method and application thereof
CN101292952A
Traditional Chinese medicine composition for preventing ulcerative colitis
CN112156092A
Application of glycyrrhizic acid and glycyrrhetic acid in preparing medicine for inflammatory enteropathy
CN1846705A
